Executive Chairman Peter Leys commented, “In the year’s opening quarter, all three of our segments performed well. Materialise Software and Materialise Medical, which continue to invest in both sales and marketing and research and development, combined healthy double-digit revenue growth rates with solid double-digit EBITDA margins. In spite of the continuing macro-economic uncertainties, in particular in the automotive sector, Materialise Manufacturing also realized growth, both in terms of revenue and, more significantly, in terms of EBITDA. We believe we are on track to meet our financial guidance for 2019.”
Fluidda announces a new phase in its collaboration with Materialise, to expand personalized treatment options in the respiratory care, building on its image based software. As part of the partnership, Materialise invests €2.5 million in Fluidda and Wilfried Vancraen, founder and CEO of Materialise, will join the board of directors at Fluidda.
Executive Chairman Peter Leys commented, “2018 has been a good year for Materialise. Our annual revenues grew by 30% to 184,721 kEUR, our Adjusted EBITDA grew by 61% to 23,526 kEUR, and our deferred revenue from license and maintenance fees increased 3,883 kEUR to 22,606 kEUR, all at the higher end of the range we forecasted at the beginning of the year. In addition, cash flow from operating activities in 2018 was 28,321 kEUR compared to 9,951 kEUR in 2017, and, as a result of the capital we raised in 2018, our cash and cash equivalents at the end of 2018 totaled 115,506 kEUR compared to 43,175 kEUR at the end of last year. This financial strength positions us well to capture new growth opportunities going forward, even if the macro-economic conditions become less favorable.”
PLYMOUTH, Mich., Nov. 27, 2018 – Materialise, in collaboration with Carestream Health, is developing a work-in-progress zero footprint deployment of their pre-operative planning solution for orthopaedists, leveraging Materialise’s OrthoView software. Thanks to enterprise-wide licensing and an enterprise imaging-integrated zero footprint deployment, Materialise and Carestream will be able to give surgeons the freedom to plan procedures in a standard browser, eliminating the requirement for additional software.
CHICAGO – (Nov. 26, 2018). Materialise NV (Nasdaq: MTLS), a world leading 3D printing solutions provider, is working with partners to remove uncertainty and confusion for hospitals and physicians who are incorporating 3D printing into their diagnostic and surgical planning processes.
Materialise has launched a certification program that allows printer manufacturers that partner with the company to have products tested and validated as being fully compatible with Materialise Mimics inPrint software. inPrint is the first and only software to gain clearance from the FDA to develop 3D printed anatomical models for diagnostic and surgical planning uses. The inPrint software is printer- and material-agnostic, allowing Materialise to develop partnerships and solutions to meet a range of hospital and clinician requirements.